October 16, 2024 06:30 AM EDT
Deals
R&D

Take­da parts ways with Wave Life Sci­ences even with Hunt­ing­ton’s tri­al win

Ayisha Sharma

News Reporter

Take­da will not move for­ward with Wave Life Sci­ences on a Hunt­ing­ton’s dis­ease drug, end­ing their col­lab­o­ra­tion that first start­ed in 2018 with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Q&A: Sanofi’s R&D head re­flects on his first year, a post-Dupix­ent fu­ture, and find­ing an iden­ti­ty

Seek­ing to treat obe­si­ty drug side ef­fect, Neu­ro­gas­trx re­leas­es da­ta on drug for GLP-1-as­so­ci­at­ed nau­sea, vom­it­ing

J&J trims pipeline, in­clud­ing two mid-stage neu­ro­science stud­ies

GSK sues Mod­er­na over mR­NA vac­cine patents, seeks 'rea­son­able roy­al­ty'

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times